Stay updated on Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the phase II trial studying the combination treatment of autologous dendritic cells pulsed with tumor lysate antigen vaccine and nivolumab for treating patients with recurrent glioblastoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:22.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    45%
    Check dated 2024-05-22T20:28:53.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:32:05.000Z thumbnail image

Stay in the know with updates to Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.